Global Presence ACM Global Laboratories operates in over 65 countries with dedicated facilities in the US, UK, India, and Singapore, providing substantial international reach to support multinational clinical trials and diagnostic services.

Expanding COVID-19 Capabilities The company's recent involvement in COVID-19 vaccine and therapeutic trials highlights a strategic focus on infectious disease testing, offering opportunities to collaborate on current and future pandemic-related studies.

Broad Testing Portfolio Performing more than 20 million tests annually across pathology, microbiology, molecular diagnostics, and toxicology, ACM offers a versatile suite of services that can be tailored to various clinical and research needs, presenting opportunities for customized testing solutions.

Acquisition Strategy The company's recent acquisition of DrugScan Inc. underscores a growth strategy aimed at expanding testing capabilities and client base, opening channels for leveraging complementary lab services and building integrated testing solutions.

Industry Positioning As a leading independent laboratory with a robust revenue stream and substantial employee base, ACM Global Laboratories is well-positioned to scale partnerships in biotechnology, pharmaceutical research, and infectious disease testing, making it an attractive partner for expanding clinical trial collaborations.